PRESENTATION {#sec1-1}
============

A 23-year-old man was presented with slowly progressive bilateral decreasing vision over the past 3 years. He had no remarkable medical, surgical or family history of ocular or systemic disease. Best-corrected visual acuity (BCVA) was 20/200 in both eyes with -1-0.75×90 and -1.50-0.50×90 correction in the right and left eyes, respectively. Anterior segment examination revealed diffuse neovascularization of iris (NVI) in both eyes \[[Figure 1](#F1){ref-type="fig"}\]. Diffuse capillary non-perfused areas associated with occluded retinal vessels in both eyes, and fibrovascular membrane with traction on the macula in the left eye were present in dilated fundus examination \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\]. Moreover, on wide field fluorescein angiography (FAG), extensive capillary non-perfused areas, occluded vessels, and retinal artery narrowing were observed \[Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}\]. A complete systemic workup including detailed thrombophilia factors was requested among which a reduced level of circulating anti-thrombin III was significant. The patient was managed by pan-retinal laser photocoagulation (PRP) bilaterally in addition to intravitreal bevacizumab injection in the right eye.

![Slit lamp photography shows diffuse iris neovascularization around the pupil.](JOVR-10-493-g001){#F1}

![Color fundus photograph of the right eye shows pale optic disc, severe arterial narrowing, occluded vessels, shunt vessels and mild fibrosis.](JOVR-10-493-g002){#F2}

![Fundus photograph of the left eye shows a fibrovascular membrane on the optic disc with macular traction, retinal arterial narrowing occluded vessels, shunt vessels.](JOVR-10-493-g003){#F3}

![Wide-field FAG of the right eye shows diffuse hypo fluorescence (capillary non-perfused area), occluded vessels and shunt vessels.](JOVR-10-493-g004){#F4}

![Wide-field FAG of the left eye shows significant hypo fluorescence due to occluded vessels, disc leakage, peripapillary shunt and neovascular capillary networks.](JOVR-10-493-g005){#F5}

DISCUSSION {#sec1-2}
==========

Anti-thrombin III is a potent inhibitor of reactions in the coagulation cascade. Its main duty is to virtually inhibit all coagulation enzymes to some extent. Congenital anti-thrombin III deficiency is an autosomal dominant disorder in which an individual inherits one copy of a defective gene. This condition leads to an increased risk of venous and arterial thrombosis with onset of clinical manifestations typically appearing in young adulthood.\[[@ref1][@ref2]\] Acquired anti-thrombin III (AT III) deficiency has been reported in metabolic acidosis, hyper-lipoproteinemias, chronic liver diseases especially liver cirrhosis, active inflammatory bowel diseases, nephrotic syndrome, hemodialysis and disseminated intravascular coagulation.\[[@ref3]\] Anti-thrombin deficiency is associated with a 5 to 50-fold increased risk for venous thrombosis.\[[@ref4]\]

Since the average age in patients affected by retinal vein occlusion (RVO) is 65,\[[@ref5]\] the majority of RVO cases are mainly secondary to underlying cardiovascular diseases.\[[@ref6]\] Although there is no consensus, it seems rational to refer patients with central RVO for thrombophilia screening if they are younger than 50 years of age.\[[@ref7]\]

Herein, we reported a patient with severe retinal ischemia secondary to multiple RVO with anti-thrombin III deficiency to emphasize the importance of detection of thrombophilia in cases of vein occlusion particularly in young subjects. Ophthalmologists play a key role in approaching such cases by uncovering systemic associations and preventing vision and life-threatening conditions.
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